TITLE

Stroke drug earns phase-3 trial

AUTHOR(S)
Walters, Kath
PUB. DATE
February 2007
SOURCE
BRW;2/8/2007, Vol. 29 Issue 5, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that biotechnology company Neuren Pharmaceuticals Ltd. has received approval from the U.S. Food and Drug Administration (FDA) to begin a phase three drug trial of Glypromate, which is designed to prevent cognitive impairment in heart-surgery patients. If the trial is successful, it can apply for FDA approval to begin selling the drug. The trial, which cost $10 million and involve a total of 520 patients, is expected to take 18 months.
ACCESSION #
24625884

 

Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;8/17/2009, Vol. 20 Issue 157, p4 

    This section offers news briefs on the biotechnology industry. Oxygen Biotherapeutics Inc. has received approval to start its Phase II, dose-escalation trial in Switzerland covering the use of Oxycyte in traumatic brain injury. DNage's investigational new drug application for Prodarsan has been...

  • When will the bear move on? Brower, Vicki // EMBO Reports;Nov2002, Vol. 3 Issue 11, p1015 

    This article reports on problems faced by biotechnology industry in the U.S. in 2002. The year 2002 has not been kind to biotechnology: the industry has lost nearly half its value since January. Recent rejections of new drug applications from various bio-technology companies by the U.S. Food and...

  • suzhou PHARMA SERVICES.  // Contract Pharma;2013 Corporate Capabilities & Contract Services Directory, p212 

    The article focuses on Lyndhurst, New Jersey-based pharmaceutical company Suzhou Pharma Services. It mentions that Suzhou is a contract and manufacturing organization working with U.S. Food and Drug Administration (FDA) and Chinese government-approved drugs. It adds that the company provides...

  • Trials not reporting age, race, gender.  // Ophthalmology Times;04/15/2001, Vol. 26 Issue 8, p20 

    States the drug and biotechnology companies are not fully reporting to the United States Food and Drug Administration (FDA) the gender, racial and age makeups of subjects in their clinical trials. Goal of the rule issued by FDA requiring companies to tabulate age, race and gender of subjects...

  • FDA, Research Organizations Seek to Bolster Drug Submissions. Wechsler, Jill // Applied Clinical Trials;Sep2013, Vol. 22 Issue 9, p12 

    The article informs that the U.S. Food and Drug Administration (FDA) has increased fees paid by pharma and biotech firms for 2014 authorized by the Prescription Drug User Fee Act (PDUFA). It states that decline in anticipated New Drug Applications (NDAs) submitted to the FDA can result in...

  • News In Brief. Waltz, Emily; Jones, Philip; Vermij, Peter; Katsnelson, Alla; Mitchell, Peter // Nature Biotechnology;Jun2006, Vol. 24 Issue 6, p601 

    The article offers news brief related to biotechnology industries in the U.S. A study conducted by the U.S. Food and Drug Administration found out a weak relationship between financial conflict and voting behavior among its members. The Syngenta International AG launched a Bioventure capital...

  • Biotech gets good news, twice. Henderson, Tom // Crain's Detroit Business;6/23/2008, Vol. 24 Issue 25, p2 

    The article reports that according to Aastrom Biosciences Inc., the U.S. Food and Drug Administration has approved the use of cardiac repair cells for Phase II clinical trials of the treatment of dilated cardiomyopathy. Aastrom Biosciences makes regenerative medicines based on stem cells. The...

  • CLINIC ROUNDUP.  // BioWorld Today;10/15/2009, Vol. 20 Issue 199, p8 

    This section offers news briefs related to biotechnology. Intercell AG of Vienna, Austria, entered phase III development for their travelers' diarrhea vaccine patch. ZyStor Therapeutics Inc. received clearance from the U.S. Food and Drug Administration for a phase I study of its enzyme...

  • Protocol Amendments: A Costly Solution. Getz, Kenneth A. // Applied Clinical Trials;May2011, Vol. 20 Issue 5, p28 

    The article offers insights on the cost needed to enforce protocol amendments for clinical trials in the U.S. It mentions the use of benchmarking for incidence and effect of protocol amendments in mid-sized to large pharmaceutical and biotechnology companies. It highlights cardiovascular and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics